|Bid||23.21 x 900|
|Ask||23.25 x 800|
|Day's Range||22.32 - 23.15|
|52 Week Range||21.60 - 44.66|
|Beta (5Y Monthly)||1.08|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 25, 2023 - Jul 31, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.08|
Subscribe to Yahoo Finance Plus to view Fair Value for TDOCLearn more
Regardless of your investing experience or risk tolerance, putting cash into stocks takes a certain tolerance for volatility and uncertainty. Investing in wonderful businesses, diversifying the ones you own, holding onto those great companies through the market's highs and lows, and avoiding traps like market timing can help you outpace the returns of the average retail investor through the years. Pfizer (NYSE: PFE) caught the attention of many investors when it became one of the leading contenders in the race to get a COVID-19 vaccine to market.
No bear market period is exactly alike, and the prolonged volatility of the past year-plus understandably has some investors frustrated. Patience and fortitude are warranted to be a long-term investor, and the current market environment continues to prove that point more than ever. Teladoc Health (NYSE: TDOC) hasn't been the portfolio winner many investors had hoped for over the last year, and shares of the telehealth giant have experienced far more volatility than the average healthcare stock.
Last year may have scared investors away from the stock market. As the market recovers, some growth stocks with strong fundamentals may thrive. Two such revolutionary companies are virtual healthcare leader Teladoc Health (NYSE: TDOC), and robotic surgery leader Intuitive Surgical (NASDAQ: ISRG).
As we can see in the chart below, putting money into the stock market before the recession would have been a wise idea. Earlier, I briefly mentioned the idea of low valuations being a reason to invest.
Cathie Wood's ARK Invest ETFs are on the rebound in 2023 after plunging in 2021 and 2022. Five ARK Invest stocks to watch include Tesla.
Teladoc (TDOC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
CRISPR Therapeutics (NASDAQ: CRSP) and Teladoc Health (NYSE: TDOC) both score a win when it comes to innovation in healthcare. CRISPR has developed a gene-editing approach that aims to fix faulty genes responsible for disease. Teladoc leads in telemedicine, allowing patients to visit doctors from the comfort of an armchair at home.
Given the market volatility over the past few years, some investors are questioning whether they should still be putting their hard-earned money into the stock market. Let's take a closer look at two excellent growth stocks to buy right now: Teladoc Health (NYSE: TDOC) and DexCom (NASDAQ: DXCM). Last year was a horror show for Teladoc.
These stocks are both trading at lower prices now than the lows they hit during the 2020 market crash.
The good news is you really don't have to -- and you still can win in the stock market. The success of Moderna's (NASDAQ: MRNA) blockbuster coronavirus vaccine helped the stock soar earlier in the pandemic. Here's why they shouldn't: The vaccine represents just the beginning of Moderna's growth story.
Teladoc Health (NYSE: TDOC) stock has been on a crazy ride the past few years, from a high of $308 in February of 2021 to a low of $21.60 this past February. The healthcare company has solid name recognition as an early mover in telehealth. Here are three things that smart investors know about Teladoc.
Billionaire investor Warren Buffett says, "The stock market is a device for transferring money from the impatient to the patient." There are many impatient investors right now dumping shares of companies that have been struggling over the past year or so. Two such examples are PayPal Holdings (NASDAQ: PYPL) and Teladoc Health (NYSE: TDOC).
Cathie Wood looks for stocks that are leading innovators. But the stocks that fit that mold aren't always leaders when it comes to delivering huge returns over the short term. On the contrary, quite a few of the stocks in Wood's Ark Invest portfolios have been big losers.
Teladoc Health's (TDOC) cash-generating abilities are boosted by the growing number of visits and memberships.
A lot has changed for Teladoc Health (NYSE: TDOC) since the company's IPO in 2015. The stock is still reeling from management's dramatic misstep in overpaying for Livongo in 2020. Teladoc spent years as a telehealth company, where patients could meet with healthcare professionals digitally.
Virtual visits give doctors and patients more flexibility and can make it easier to stay on top of chronic conditions like diabetes and hypertension. Teladoc Health's (NYSE: TDOC) share price has nosedived in the past few years, but the business itself has evolved and become much bigger than it was before the pandemic began. The company's success can be illustrated with just one impressive stat: its sharp increase in virtual visits.
The bear market seems like it's never ending, but investors shouldn't be discouraged. Bear markets are inevitable, as are recessions, but so too are the recoveries that follow. Buying and holding is what has made investors like Warren Buffett hugely successful over the years.
Finding the best MedTech stocks to watch in May can be a challenge. After all, the category is huge. MedTech encompasses many types of sectors like medical devices, cloud applications, artificial intelligence (AI), and diagnostic systems. Yet there are many positive catalysts for the industry. Just look at AI. A recent study from JAMA Internal Medicine highlights how innovation is improving healthcare. It compared human doctor advice to that of ChatGPT. The results? Well, based on a peer review
In need of healthcare exposure in your portfolio? Consider holding these three promising companies forever.
Teladoc Health (NYSE: TDOC) and InMode (NASDAQ: INMD) both operate in high-growth industries. Teladoc is a leader in telemedicine. InMode specializes in selling devices in the minimally invasive and non-invasive aesthetics market.
Key Insights Significantly high institutional ownership implies Teladoc Health's stock price is sensitive to their...
On April 26, Teladoc Health reported its earnings numbers for the period ended March 31. A big positive was that the business's growth rate remained resilient. While that's not as strong as the figures achieved during the early stages of the pandemic, when the stock was a red-hot buy, the growth rate hasn't fallen into the negative.
Investors remain puzzled due to persistent macro challenges, continued interest rate hikes, and the regional banking crisis. Given the ongoing uncertainties, sectors that are resilient during economic downturns could offer attractive investment opportunities. While not entirely immune to recessionary conditions, healthcare companies have the ability to navigate a tough macro backdrop due to the essential nature of their products and services. An increased focus on health since the Covid-19 pande
Teladoc Health (NYSE: TDOC) is finally getting some love from investors. The company's latest quarterly report was also well-received by the market, which helped jolt its stock further. Before jumping on the bandwagon, it's essential to look deeper into Teladoc's operations and determine whether the company has solid long-term prospects.
Virtual healthcare company Teladoc Health (NYSE: TDOC) experienced some exceptional gains during the worst of the pandemic. When the pandemic subsided and hospitals reopened, investors expected telehealth services would no longer be in demand and dumped the company's stock, causing it to plummet. Teladoc, on the other hand, is demonstrating that it can not only survive but thrive in the post-pandemic market.